Clinical lung and heart/lung transplantationLymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases☆
Section snippets
Patients
All patients who underwent lung or heart–lung transplantation at Barnes–Jewish Hospital, a tertiary care affiliate of Washington University School of Medicine, St Louis, MO, between July 1, 1988 and January 1, 2000, were included in this study. The assessment of outcomes was continued through April 15, 2000, the end of the study period.
PTLD was diagnosed in 30 of 494 recipients. For reference in this study, the cases of PTLD were serially numbered in chronologic order according to the
Diagnosis, classification and management of PTLD
Throughout the study period, evaluation of clinically apparent abnormalities led to the detection of PTLD. The diagnosis was confirmed by biopsy or surgical excision (n = 26), fine needle aspiration (n = 2) or autopsy (n = 2). One of the cases that was initially diagnosed by needle aspiration was subsequently corroborated by post-mortem pathology. The date of confirmation was used as the date of diagnosis in the analyses.
A pathologist (M.D.K.) who was blinded to the clinical information
Data analysis
The date of transplantation, date of death or last follow-up, cause of death, site(s) of PTLD, treatment for PTLD and response to treatment were recorded. Age at transplantation and age at PTLD diagnosis were calculated. For statistical analysis, cases were classified according to the time of onset and the site(s) of PTLD and were analyzed in several ways: “Early” vs “Late”; “Thoracic” (any site in chest, with or without an extrathoracic site) vs “Extrathoracic” (sites exclusively outside
Results
Between July 1, 1988 and January 1, 2000, 494 adult patients underwent lung (n = 491) or heart–lung (n = 3) transplantation at Barnes–Jewish Hospital (Table I). Kaplan–Meier survival rates for these recipients were 84% at 1 year, 70% at 3 years and 52% at 5 years after transplantation. The mean (±SD) duration of observation for the recipients was 3.4 ± 2.6 years (median 2.8 years), and the study included 1687 patient-years of follow-up. Three hundred eighty-four recipients had follow-up beyond
Discussion
Post-transplantation lymphoproliferative disease has become a well-known complication of lung transplantation, but it has not been characterized completely. A synopsis of the published series of PTLD after lung transplantation is presented in Table IV. Most studies have reported small cohorts of recipients that have been monitored for a relatively short time after transplantation. Although the follow-up period has varied and has not always been clearly specified, the incidence of PTLD in these
References (26)
- et al.
A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients
Chest
(1999) - et al.
Analysis of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation
Surg
(1996) - et al.
The Registry of the International Society for Heart and Lung Transplantationsixteenth official report—1999
J Heart Lung Transplant
(1999) - et al.
Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation
Int J Radiat Oncol Biol Phys
(1998) - et al.
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
Blood
(1995) Neoplastic complications of organ transplantation
- et al.
Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients
Clin Transplant
(1992) - et al.
Analysis of non-Hodgkin’s lymphomas in organ transplant recipients
Transplant Rev
(1995) Neoplastic complications of transplantation
Semin Respir Infect
(1993)The role of immunosuppression in lymphoma formation
Springer Semin Immunopathol
(1998)
Posttransplant lymphoproliferative disease in thoracic organ transplant patientsten years of cyclosporine-based immunosuppression
J Heart Lung Transplant
Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naive lung transplant recipient
Am J Respir Crit Care Med
Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients
AJR
Cited by (103)
Imaging in Lung Transplantation: Surgical Techniques and Complications
2023, Radiologic Clinics of North AmericaIncidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry
2020, Journal of Heart and Lung TransplantationLiving-donor single-lobe lung transplantation for pulmonary hypertension due to alveolar capillary dysplasia with misalignment of pulmonary veins
2020, American Journal of TransplantationPosttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients
2018, Annals of Thoracic SurgeryCitation Excerpt :Similarly, although larger studies have reported a PTLD rate of 5.0% among all lung transplant recipients regardless of EBV status, this is the first study to provide an incidence estimate from a national database [12, 13]. That 60.8% of PTLD cases were diagnosed in the first year after transplant likely reflects that EBV D+/R− patients appear to be at higher risk for early PTLD than non-EBV D+/R− patients, where only 25% to 46.7% occur in the first year [13–15]. The 43.8% 1-year mortality from PTLD and 405-day median survival is consistent with other reported rates among lung transplant recipients, although some single centers have found higher survival, upward of 66.6% at 5 years [2, 12, 13].
Common Causes of Diffuse Alveolar Damage in the Pulmonary Allograft
2018, Practical Pulmonary Pathology: A Diagnostic Approach A Volume in the Pattern Recognition SeriesPosttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation
2017, Clinics in Chest Medicine
- ☆
Supported by the National Heart, Lung and Blood Institute; National Institutes of Health (Grant K23 HL04236) (Dr Yusen); and by the Rosemary and I. Jerome Flance Professorship in Pulmonary Medicine (Dr. Trulock).